Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CS3002 in advanced solid tumors
NCT04162301Phase 1Terminated
- Sponsor
- CStone Pharmaceuticals
- Start
- Dec 2019
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CS3002 in solid tumor (advanced stage), sponsored by CStone Pharmaceuticals. Primary endpoint: Number of participants with adverse events as assessed by CTCAE v5.0. Started Dec 2019; status: terminated.
02
Drugs
CS3002
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04162301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04162301.